open access

Vol 7, No 1 (2005)
Published online: 2005-05-06
Get Citation

Efficacy of therapy and secondary prophylaxis of deep vein thrombosis with low-molecular-weight heparin

Zbigniew Krasiński, Grzegorz Oszkinis, Ryszard Staniszewski, Krzysztof Lewandowski, Rodryg Ramlau, Beata Krasińska, Marcin Gabriel, Mirosław Czyżak, Wacław Majewski
Chirurgia Polska 2005;7(1):43-52.

open access

Vol 7, No 1 (2005)
Published online: 2005-05-06

Abstract

Background: There is a strong correlation between deep vein thrombosis (DVT) occurrence and some malignant diseases. So far, no principles of management with patients who present DVT, during the course of cancer, have been established. The objective of this study was to evaluate the results of treatment and secondary prophylaxis with LMWH in patients with malignancy complicated by venous thrombosis.
Material and methods: A group of 20 patients with proximal deep vein thrombosis (studied group-SG), in whom DVT was accompanied by cancer, and one of 30 patients with proximal DVT without malignancy jedsymptoms (control group-CG) were studied. The treatment protocol assumed DVT treatment with LMWH (nadroparin) during a 6-month period in both groups. The drug was administered subcutaneously in a twice daily dose 0.1 ml per 10 kg every 12 hours for the first 10 days and subsequently 0.1 ml per 10 kg once daily for a 6-month period. The assessment of treatment results was based on venography and Doppler ultrasound scans. The incidence of complications was analyzed.
Results: The study results showed no statistically significant differences in the treatment results between both groups. The lack of complete venous vessel recanalization was indicated in both groups after a 6-month therapy. No serious complications in either group was observed.
Conclusions: Our current study suggests that LMWH in secondary prophylaxis, in a dose equal to half of the therapeutic dose, is a safe and effective alternative to oral anticoagulants in patients with coexisting malignant disease.

Abstract

Background: There is a strong correlation between deep vein thrombosis (DVT) occurrence and some malignant diseases. So far, no principles of management with patients who present DVT, during the course of cancer, have been established. The objective of this study was to evaluate the results of treatment and secondary prophylaxis with LMWH in patients with malignancy complicated by venous thrombosis.
Material and methods: A group of 20 patients with proximal deep vein thrombosis (studied group-SG), in whom DVT was accompanied by cancer, and one of 30 patients with proximal DVT without malignancy jedsymptoms (control group-CG) were studied. The treatment protocol assumed DVT treatment with LMWH (nadroparin) during a 6-month period in both groups. The drug was administered subcutaneously in a twice daily dose 0.1 ml per 10 kg every 12 hours for the first 10 days and subsequently 0.1 ml per 10 kg once daily for a 6-month period. The assessment of treatment results was based on venography and Doppler ultrasound scans. The incidence of complications was analyzed.
Results: The study results showed no statistically significant differences in the treatment results between both groups. The lack of complete venous vessel recanalization was indicated in both groups after a 6-month therapy. No serious complications in either group was observed.
Conclusions: Our current study suggests that LMWH in secondary prophylaxis, in a dose equal to half of the therapeutic dose, is a safe and effective alternative to oral anticoagulants in patients with coexisting malignant disease.
Get Citation

Keywords

deep vein thrombosis; heparin; malignant diseases

About this article
Title

Efficacy of therapy and secondary prophylaxis of deep vein thrombosis with low-molecular-weight heparin

Journal

Chirurgia Polska (Polish Surgery)

Issue

Vol 7, No 1 (2005)

Pages

43-52

Published online

2005-05-06

Bibliographic record

Chirurgia Polska 2005;7(1):43-52.

Keywords

deep vein thrombosis
heparin
malignant diseases

Authors

Zbigniew Krasiński
Grzegorz Oszkinis
Ryszard Staniszewski
Krzysztof Lewandowski
Rodryg Ramlau
Beata Krasińska
Marcin Gabriel
Mirosław Czyżak
Wacław Majewski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaBy "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl